Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Quality control of flow c… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment.

Artikel i vetenskaplig tidskrift
Författare Elisabet Björklund
Irma Matinlauri
Anne Tierens
Susanne Axelsson
Erik Forestier
Stefan Jacobsson
Asa Jeppsson Ahlberg
Goran Kauric
Pentti Mäntymaa
Liv Osnes
Tarja-Leena Penttilä
Hanne Marquart
Eeva-Riitta Savolainen
Sanna Siitonen
Kerstin Torikka
Joanna Mazur
Anna Porwit
Publicerad i Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology
Volym 31
Nummer/häfte 6
Sidor 406-15
ISSN 1536-3678
Publiceringsår 2009
Publicerad vid Institutionen för biomedicin, avdelningen för klinisk kemi och transfusionsmedicin
Sidor 406-15
Språk en
Länkar dx.doi.org/10.1097/MPH.0b013e3181a1...
Ämnesord Adolescent, Bone Marrow, pathology, Bone Marrow Examination, standards, Child, Child, Preschool, Female, Flow Cytometry, standards, Humans, Male, Medical Oncology, standards, Middle Aged, Neoplasm, Residual, diagnosis, Pathology, Clinical, standards, Precursor Cell Lymphoblastic Leukemia-Lymphoma, diagnosis, Quality Control
Ämneskategorier Tumörbiologi, Hematologi

Sammanfattning

Low levels of leukemia cells in the bone marrow, minimal residual disease (MRD), are considered to be a powerful indicator of treatment response in acute lymphatic leukemia (ALL). A Nordic quality assurance program, aimed on standardization of the flow cytometry MRD analysis, has been established before implementation of MRD at cutoff level 10 as one of stratifying parameters in next Nordic Society of Pediatric Hematology and Oncology (NOPHO) treatment program for ALL. In 4 quality control (QC) rounds 15 laboratories determined the MRD levels in 48 follow-up samples from 12 ALL patients treated according to NOPHO 2000. Analysis procedures were standardized. For each QC round a compact disc containing data in list-mode files was sent out and results were submitted to a central laboratory. At cutoff level 10, which will be applied for clinical decisions, laboratories obtained a high concordance (91.6%). If cutoff level 10 was applied, the concordance would be lower (85.3%). The continuing standardization resulted in better concordance in QC3 and QC4 compared with QC1 and QC2. The concordance was higher in precursor B as compared with T-cell ALL. We conclude that after standardization, flow cytometry MRD detection can be reliably applied in international, multicenter treatment protocols.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?